Reducing oncology readmissions through a multidisciplinary discharge approach.

Authors

null

Samantha DiBenedetto

University of Virginia, Charlottesville, VA

Samantha DiBenedetto , Eric Pierce , Leah Wells , Michael Kenneth Keng

Organizations

University of Virginia, Charlottesville, VA, University of Virginia Health System, Charlottesville, VA

Research Funding

No funding received

Background: Hospital readmissions are associated with increased health care utilization and unfavorable patient outcomes. Oncology patients have an increased risk of hospital readmission compared to the general patient population. The 30-day readmission rate for cancer patients at our institution is 27.7% which is higher than the reported national average of 20.2%. We sought to reduce 30-day hospital readmission rates by 25% for solid tumor oncology patients through a prospective integrated multidisciplinary discharge approach. Methods: Hospital readmissions for adult patients with a known solid tumor cancer diagnosis admitted to the oncology service at UVA from Jan 2019 – Apr 2019 were identified. Baseline information on tumor type, reason for readmission, interventions, length of stay (LOS), and inpatient morbidity and mortality (including ICU admission and transition to hospice) were collected via retrospective review. Qualitative and quantitative tools including process maps, cause-and-effect diagrams, Pareto charts, and priority matrix were used to identify potential areas for intervention. Two PDSA cycles were implemented: daily multidisciplinary discharge rounds with physicians, nursing, social work, case management, and PT/OT (PDSA1), and a templated discharge email to patients’ primary oncology team including attending oncologist, mid-level providers, nurse coordinator, pharmacist, and urgent care team (PDSA2). An SPC chart with 3-σ limits and t-test of unequal variance with 2-sided p-value was used to evaluate impact on readmission rates from baseline to PDSA2. Results: Following PDSA1 (May 2019 – Oct 2019), the 30-day readmission was 25.7%; PDSA2 was postponed due to COVID-19, however the 30-day readmission rate remained stable during the pandemic. Following PDSA2 (Sept 2021 – Dec 2021), the 30-day readmission rate was 18.2% corresponding to an absolute decrease of 34.3% which was statistically significant (p≤0.05). This was associated with a trend towards increased LOS, rate of ICU admission, and case-mix severity index although not statistically significant. There was no significant difference in inpatient mortality or transition to hospice (Table). Conclusions: Implementation of multidisciplinary discharge rounds and templated discharge communication resulted in a significant decrease in rate of 30-day readmissions for solid tumor oncology patients. There was a trend towards increased LOS and ICU admissions without increased inpatient mortality. Improvement in discharge email compliance and implementation of an urgent symptom clinic may further reduce the 30-day readmission rate.

Baseline (n=424)
PDSA1 (n=1231)
PDSA2 (n=231)
P-value
30-day readmission rate (%)
27.7
25.7
18.2
0.046
Average LOS (days)
5.8
5.7
10.0
0.076
ICU admissions (%)
9.1
14.7
16.7
0.339
Inpatient mortality (%)
5.2
3.1
4.8
0.977
Transition to hospice (%)
15.6
16.0
16.7
0.845
Case mix index
1.66
1.68
1.94
0.287

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Quality Improvement

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 6561)

DOI

10.1200/JCO.2022.40.16_suppl.6561

Abstract #

6561

Poster Bd #

344

Abstract Disclosures

Similar Abstracts

First Author: Antonio Giuseppe Faieta

Abstract

2022 ASCO Annual Meeting

Palliative care utilization and mortality in patients who received inpatient chemotherapy.

First Author: Justine Anderson

First Author: Ayobami Gbenga Olafimihan